We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

Spruce Biosciences Stock (NASDAQ:SPRB)



Previous Close

$0.41

52W Range

$0.34 - $5.95

50D Avg

$0.41

200D Avg

$0.52

Market Cap

$16.75M

Avg Vol (3M)

$598.90K

Beta

2.37

Div Yield

-

SPRB Company Profile


Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

22

IPO Date

Oct 09, 2020

Website

SPRB Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
SPRB
S&P 500
-1.15%
3.66%
11.16%
-17.35%
-10.23%
-3.31%
-92.26%
-81.48%
-97.61%
-97.61%
-0.00%
1.75%
2.03%
4.09%
9.99%
4.29%
22.74%
39.50%
81.06%
190.18%

SPRB Financial Summary


Dec 23Dec 22Dec 21
Revenue$10.09M--
Operating Income$-51.99M$-47.28M$-42.07M
Net Income$-47.92M$-45.08M$-42.69M
EBITDA$-51.99M$-45.76M$-41.95M
Basic EPS$-1.24$-1.92$-1.83
Diluted EPS$-1.24$-1.92$-1.83

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
TERNTerns Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
XFORX4 Pharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
INZYInozyme Pharma, Inc.
ABOSAcumen Pharmaceuticals, Inc.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools